ViroXis is developing a patented topical albuterpenoid drug derived from East Indian Sandalwood oil (EISO) as a botanical antiviral therapeutic targeting human papillomavirus (HPV) skin warts. The company plans to advance product development and commercialization of its lead topical therapeutic. EISO has completed an investigational Phase IIb FDA‑approved clinical study with clinical investigators at the Children’s Hospital in Columbus, Ohio. The recent funding will be used to move the lead product into clinical trials. Management frames the program as a novel botanical drug for a prevalent skin condition that currently lacks a successful treatment. Financially, the company received a $2.5M award/investment from the Texas Emerging Technology Fund to support these activities.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2010